WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
SJIF Impact Factor 8.453
Volume 13, Issue 20, 44-57. Review Article ISSN 2277–7105

ROLE /ASSOCIATION OF MTHFR GENE WITH DOWNS SYNDROME

Shubham Anand*, Manoj Kumar Bajhaiya, Sakshi Singh, Aman Sharma, Laksh Kumar, Divyansh Kumar, Hemant Singh Patel, Moulik Choudhary, Dipanshu Kushwaha, Dipanshu Raj

School of Pharmacy, Itm University Gwalior.

Article Received on
23 August 2024,

Revised on 13 Sept. 2024,
Accepted on 03 October 2024

DOI: 10.20959/wjpr202420-33985

***Corresponding Author**
Shubham Anand
School of Pharmacy, Itm University Gwalior.

ABSTRACT

Down syndrome (DS) is a chromosomal disorder primarily caused by trisomy 21, with an incidence rate of approximately 1 in 700 live births. Recent research suggests that genetic factors, particularly methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms, play a significant role in increasing the risk of Down syndrome (DS) by disrupting folate metabolism. The MTHFR gene, responsible for encoding an enzyme crucial in the folate cycle, impacts homocysteine levels and DNA methylation processes. Mutations, especially the C677T polymorphism, have been associated with improper chromosomal segregation (nondisjunction) during meiosis, increasing the likelihood of trisomy 21. This review examines the current evidence linking MTHFR gene polymorphisms to Down syndrome (DS), highlighting how disruptions in folate metabolism may influence chromosomal stability and developmental outcomes. Additionally, we explore how nutritional interventions, including folate and vitamin B12 supplementation, could mitigate these risks by restoring biochemical pathways affected by MTHFR mutations. Understanding the genetic and metabolic contributions of the MTHFR gene may offer new perspectives on preventing chromosomal abnormalities linked to DS.

1. INTRODUCTION

Down syndrome (DS) is the most common chromosomal disorder, affecting cognitive and physical development. DS is primarily caused by the presence of an extra chromosome 21, a condition known as trisomy 21, which results from the failure of proper chromosomal segregation during meiosis. While advanced maternal age has long been identified as a risk

factor, emerging evidence suggests that genetic factors such as the methylenetetrahydrofolate reductase (MTHFR) gene may play a critical role in DS pathogenesis.[1]

The MTHFR gene encodes an enzyme essential for the metabolism of folate and homocysteine. This enzyme facilitates the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, the active form of folate, which is crucial for the remethylating of homocysteine into methionine. Methionine is vital for DNA synthesis and methylation, processes that are crucial during cell division and embryonic development. MTHFR gene variations, particularly the C677T polymorphism, cause decreased enzyme activity, which raises homocysteine levels and impairs the metabolism of folate.[2] research indicates that the MTHFR C677T polymorphism is significantly associated with an increased risk of maternal nondisjunction, a process by which chromosome pairs fail to separate properly during meiosis. This failure can result in an additional copy of chromosome 21, leading to DS. Furthermore, mothers with this MTHFR variant often exhibit lower levels of folate and vitamin B12, both of which are essential for maintaining genomic stability. Folate deficiency, in particular, has been linked to DNA hypomethylation, which can disrupt normal chromosomal segregation and increase the risk of aneuploidy, including trisomy 21.

In addition to its role in folate metabolism, MTHFR polymorphisms may also be implicated in congenital abnormalities observed in DS, such as congenital heart defects, preterm birth, and low birth weight.[3] these conditions are often more prevalent in mothers who carry the MTHFR gene mutation. Understanding the role of MTHFR polymorphisms in DS not only enhances our knowledge of its genetic ethology but also opens the door to preventive strategies, including folate and vitamin B12 supplementation during the preconception and pregnancy periods.

Methods

Major online databases, namely PubMed, Scopus, and Web of Science, were searched up to April 24, 2015 using the following terms “MTHFR gene”, “Homocystinuria”, “cardiovascular diseases”, “homocysteine” and “Metabolic Syndrome”. titles and abstracts of the retrieved articles were initially screened for relevance. Full-text articles were then reviewed to confirm their eligibility based on the inclusion criteria. Data from the selected studies were systematically extracted and analysed. Data synthesis included qualitative analysis and meta-analysis where applicable, with sensitivity analyses to ensure robustness of

findings. Ethical considerations were upheld by accurately reporting and interpreting data from existing studies."

2. Down syndrome's Genetic basis

Trisomy 21—commonly referred to as Down syndrome—is one of the most common chromosomal disorders. distinguished by having an extra copy of chromosome 21. The extra genetic material has an impact on normal development, which leads to the syndrome's characteristic phenotypes. Understanding the genetic basis of Down syndrome is crucial for elucidating its pathophysiology and potential interactions with other genetic factors, such as those involving the MTHFR gene.

2.1 Chromosomal abnormalities

Down syndrome primarily results from nondisjunction during meiosis, which leads to the production of gametes with an extra chromosome 21. Upon fertilization, this results in a zygote with three copies of chromosome 21, a condition known as Trisomy 21.[5] Approximately 95% of Down syndrome cases are attributed to this chromosomal anomaly. The remaining 5% of cases are due to other chromosomal variations, such as translocation (Where part of chromosome 21 is attached to another chromosome) or mosaicism (Where only some cells have the extra chromosome).[4]

2.2 Genetic mechanisms

The presence of an extra chromosome 21 leads to the overexpression of genes located on this chromosome. This gene dosage effect disrupts normal cellular function and contributes to the development of Down syndrome's characteristic features, including cognitive impairment, distinct facial features, and increased susceptibility to various health conditions. Studies have shown that overexpression of genes such as DYRK1A and APP, which are located on chromosome 21, may play a role in the neurodevelopmental and neurological aspects of Down syndrome.[5] The disruption of normal gene dosage balance affects numerous pathways, including those involved in cellular signalling, metabolism, and development. For instance, increased levels of oxidative stress and altered mitochondrial function have been implicated in the pathology of Down syndrome.[6] Additionally, the presence of an extra chromosome 21 can lead to an imbalance in protein expression levels, affecting various physiological systems and contributing to the diverse clinical manifestations of the syndrome.

2.3 Genetic Variation and Phenotypic expression

The phenotypic variability observed in individuals with Down syndrome can be influenced by factors beyond the extra chromosome 21. Genetic background, epigenetic modifications, and environmental factors can interact with the genetic predisposition conferred by Trisomy 21, leading to variability in clinical presentation (7). This includes differences in cognitive ability, physical features, and susceptibility to associated medical conditions.

Table 1: Comparison of MTHFR Variants Across Populations.

Population	Prevalence of C677T (%)	Prevalence of A1298C (%)	Reference
Caucasian	10-15%	7-10%	Hobbs et al., 2000
Asian	5-10%	12-15%	Shen et al., 2013
Indian	15-20%	10-12%	Rai et al., 2017

3. Role of the MTHFR Gene

An important enzyme in the metabolism of folate is encoded by the MTHFR gene (methylenetetrahydrofolate reductase) and homocysteine, two substances vital for numerous physiological processes. Variants in the MTHFR gene can influence the levels of these substances, impacting various health outcomes and potentially interacting with genetic conditions such as Down syndrome.

3.1 Function of the MTHFR Gene

The MTHFR enzyme catalyses the conversion of 5,10-methylenetetrahydrofolate into 5-methyltetrahydrofolate, which is the active form of folate. The remethylating of homocysteine to methionine, an amino acid necessary for other methylation events in the body, depends on this mechanism.[8] Entire cellular activity, including DNA synthesis and repair, depends on this system operating effectively.

3.2 Common Mutations and Their effects

Two common polymorphisms in the MTHFR gene are C677T and A1298C. The C677T mutation results in a thymine substitution for cytosine at position 677, leading to a thermolabile variant of the enzyme with reduced activity.[9] Individuals homozygous for this mutation typically have lower enzyme activity and elevated levels of homocysteine in their blood.[10] The A1298C mutation, which involves a substitution at position 1298, also impacts enzyme function but to a lesser extent compared to C677T.[11]

The presence of these mutations can result in elevated homocysteine levels, which have been associated with an increased risk of cardiovascular diseases, neural tube defects, and other health issues. The interaction between MTHFR mutations and folate status is critical, as adequate folate intake can mitigate some of the adverse effects associated with these genetic variants.[12]

3.3 MTHFR Gene and Down syndrome

The role of the MTHFR gene in Down syndrome is less clear compared to its involvement in other conditions. The main cause of Down syndrome is an extra copy of chromosome 21, leading to a gene dosage effect. However, some studies have explored potential interactions between MTHFR gene variants and Down syndrome. Research has suggested that individuals with Down syndrome may have altered folate metabolism, which could potentially be influenced by MTHFR gene mutations. For example, some studies have indicated that MTHFR polymorphisms might affect the levels of homocysteine and folate in individuals with Down syndrome, possibly impacting their overall health and development.[13]

Additionally, the interaction between MTHFR mutations and other genetic or environmental factors may influence the severity of Down syndrome's clinical features, although evidence remains mixed and further research is needed to clarify these associations.[14]

3.4 Clinical implications

Understanding the role of the MTHFR gene in relation to Down syndrome has potential clinical implications. Genetic testing for MTHFR mutations could provide insights into the folate metabolism status of individuals with Down syndrome, potentially guiding nutritional and therapeutic interventions.[15]

4. Association between MTHFR and Down syndrome

The association between the MTHFR gene and Down syndrome has been a subject of interest in genetic research, particularly regarding how MTHFR polymorphisms might influence the clinical manifestations and overall health of individuals with Down syndrome. While the main cause of Down syndrome is an extra copy of chromosome 21., the role of MTHFR gene variants in modifying the phenotype or influencing associated health conditions is an area of ongoing investigation.

Table 2: Relationship between MTHFR, Homocysteine and Down Syndrome Complications.

MTHFR Variant	Homocysteine Level	Health Complications in Down Syndrome	Clinical Management Options
C677T	Elevated	Cardiovascular disease, developmental delays	Folate and B12 supplementation, cardiovascular monitoring
A1298C	Mild elevation	Cognitive impairment, mental health issues	Folate monitoring, mental health support
Both (Compound)	Significantly elevated	Severe cognitive deficits, increased risk for vascular disease	Intensive nutritional therapy, multidisciplinary care

4.1 Overview of current research

Several studies have explored the potential link between MTHFR gene polymorphisms and Down syndrome, although findings have been varied. The MTHFR gene's role in folate metabolism and homocysteine regulation suggests that its variants might impact individuals with Down syndrome, given the known effects of folate on neural development and other health outcomes.[16]

One study investigated the prevalence of MTHFR C677T polymorphism in individuals with Down syndrome and found that this variant was more common in this population compared to controls.[17] The research indicated that the presence of the C677T mutation might be associated with altered folate levels, which could influence the severity of certain features of Down syndrome. However, the clinical significance of this association remains unclear, and results across studies have been inconsistent.

4.2 Mechanistic insights

The potential mechanisms by which MTHFR variants might affect Down syndrome involve several pathways. Elevated homocysteine levels, which are often associated with MTHFR mutations, have been linked to various health issues, including cardiovascular diseases and neural tube defects.[18] In individuals with Down syndrome, altered homocysteine metabolism due to MTHFR polymorphisms could potentially exacerbate certain health conditions or developmental delays.

Additionally, folate is crucial for DNA synthesis and repair, and its metabolism might be disrupted in the presence of MTHFR mutations. This disruption could potentially interact

with the genetic background of Down syndrome, where additional chromosomal material may already be affecting cellular processes and development.[19]

4.3 Clinical Implications and Controversies

While some studies suggest a possible association between MTHFR gene variants and Down syndrome, the clinical implications of these findings remain debated. For instance, the impact of MTHFR polymorphisms on the clinical management of Down syndrome, such as folate supplementation or other therapeutic interventions, has not been firmly established.[20]

Conflicting results in the literature may stem from variations in study design, sample sizes, and population characteristics. For example, while some studies report significant associations, others find no clear link between MTHFR variants and Down syndrome features.[21] This inconsistency highlights the need for further research to clarify the relationship and understand its potential clinical relevance.

4.4 Future research directions

Future research should aim to address the gaps identified in current studies. Large-scale, well-controlled studies are needed to determine whether MTHFR gene polymorphisms contribute to variability in Down syndrome phenotypes and whether they have any practical implications for patient management. Investigating the interaction between MTHFR mutations and other genetic or environmental factors could provide a more comprehensive understanding of their role in Down syndrome.[22]

5. Clinical implications

The function of MTHFR polymorphisms, specifically A1298C and C677T, in folate metabolism and homocysteine regulation presents potential clinical implications for individuals with Down syndrome. While Down syndrome is caused by trisomy 21, MTHFR polymorphisms could influence the risk of additional health complications, particularly those related to neural development, cardiovascular health, and metabolism.[23]

Table 3: Clinical Implications of MTHFR Polymorphisms.

Polymorphism	Effect on Health in Down Syndrome	Suggested Clinical Management
C677T	Elevated homocysteine, risk of cardiovascular disease	Folate and vitamin B12 supplementation
A1298C	Possible contribution to cognitive deficits,	Regular monitoring of folate levels, neurodevelopmental

	developmental delays	support
Both (C677T & A1298C)	Compound heterozygosity may result in greater impairment	Intensive management of folate metabolism, targeted therapies

5.1 Folate Metabolism and Neurodevelopment

Folate is essential for the synthesis, repair, and methylation of DNA., processes that are vital for proper neural development. In individuals with Down syndrome, the overexpression of genes on chromosome 21 may already predispose them to oxidative stress and neurodevelopmental abnormalities. MTHFR mutations, particularly C677T, reduce enzyme activity, leading to elevated homocysteine levels and impaired folate metabolism.[24] Studies have shown that such disruptions in folate metabolism may exacerbate neurodevelopmental delays and cognitive deficits in individuals with Down syndrome.[25]

In clinical settings, this suggests that monitoring folate and homocysteine levels in patients with Down syndrome could be critical for early intervention and prevention of further neurological complications. Some clinicians advocate for folate supplementation in individuals with both Down syndrome and MTHFR polymorphisms, though the effectiveness and long-term outcomes of this intervention require more research.[26]

5.2 Cardiovascular health

Elevated homocysteine levels, a result of impaired MTHFR function, are a well-known risk factor for cardiovascular diseases, including atherosclerosis and thrombosis.[27] For individuals with Down syndrome, who may already be at higher risk for congenital heart defects and other cardiovascular abnormalities, the presence of MTHFR mutations can further increase the risk of cardiovascular complications.[28]

Some clinical studies have explored the potential benefits of folate and vitamin B12 supplementation in lowering homocysteine levels and reducing cardiovascular risk in individuals with MTHFR mutations.[29] In individuals with Down syndrome, such interventions could have dual benefits: reducing cardiovascular risk and supporting neurodevelopment through improved folate metabolism.

5.3 Potential for personalized treatment

The identification of MTHFR polymorphisms in individuals with Down syndrome may also pave the way for more personalized approaches to treatment and management. Genetic

screening for MTHFR variants could allow clinicians to stratify patients based on their risk for specific complications, such as cardiovascular diseases or neurodevelopmental delays.[30] Tailoring interventions, such as folate or vitamin B12 supplementation, based on the genetic profile of the individual could improve outcomes and quality of life for those with Down syndrome.[31]

5.4 Challenges and Controversies

Despite the potential clinical benefits, the relationship between MTHFR polymorphisms and health outcomes in Down syndrome remains controversial. Some studies have found no significant associations between MTHFR variants and major health complications, leading some experts to caution against over-reliance on genetic screening for MTHFR polymorphisms.[32] The inconsistency in findings underscores the need for more robust, longitudinal studies to fully elucidate the clinical implications of MTHFR mutations in Down syndrome populations.

Additionally, while folate supplementation may appear beneficial, it is not without risks. Excessive folate intake, particularly in individuals without significant folate deficiency, has been linked to adverse effects, including masking of vitamin B12 deficiency and potential negative impacts on immune function.[33] Therefore, any intervention targeting MTHFR polymorphisms in Down syndrome patients must be carefully monitored and individualized.

5.5 Future directions

Further research into the clinical implications of MTHFR polymorphisms in Down syndrome is crucial. Large-scale, controlled trials are needed to confirm the efficacy of folate and vitamin B12 supplementation and to explore other therapeutic strategies. Additionally, future studies should focus on understanding how the interaction between MTHFR polymorphisms and other genetic or environmental factors influences the overall health and development of individuals with Down syndrome.[34] Personalized medicine approaches, which take into account an individual's genetic makeup, could become an important tool for improving clinical outcomes in this population.

6. CONCLUSION

The role of the MTHFR gene and its polymorphisms, particularly C677T and A1298C, has garnered significant attention for its implications in folate metabolism and homocysteine regulation. Although Down syndrome (trisomy 21) is primarily caused by the presence of an

extra chromosome 21, emerging evidence suggests that MTHFR variants may influence the risk of certain health complications in individuals with the condition. Studies indicate that MTHFR polymorphisms may exacerbate folate metabolism disruptions, which could potentially contribute to neurodevelopmental delays, cognitive deficits, and increased cardiovascular risks in individuals with Down syndrome. The association between the MTHFR gene and Down syndrome, while not directly causal, raises critical questions about how genetic variations might modify the overall clinical presentation of individuals with trisomy 21. The link between elevated homocysteine levels and cardiovascular health, in particular, warrants further investigation, given the increased predisposition to congenital heart defects in this population.

Clinically, the identification of MTHFR polymorphisms could enable more personalized therapeutic approaches, such as folate or vitamin B12 supplementation, designed to mitigate the potential consequences of disrupted folate metabolism. However, the variability in research findings underscores the need for larger, more robust studies to establish conclusive evidence on the therapeutic impact of these interventions. Moving forward, the interaction between genetic factors like MTHFR polymorphisms and the environmental or epigenetic factors that affect individuals with Down syndrome requires further exploration. A better understanding of these relationships may ultimately improve clinical management strategies, offering more targeted treatments that address the unique metabolic and developmental challenges faced by this population. In sum, while the MTHFR gene holds promise in elucidating the complexities of Down syndrome's pathophysiology, continued research is essential to fully understand its clinical significance.

SUMMARY

The review explores the role and association of the MTHFR gene with Down syndrome, focusing on the impact of MTHFR polymorphisms on folate metabolism and related clinical outcomes. The paper discusses various MTHFR polymorphisms, particularly C677T and A1298C, and how they influence enzyme activity and homocysteine regulation. While Down syndrome is primarily caused by trisomy 21, the presence of MTHFR variants can exacerbate metabolic and developmental challenges in affected individuals.

The review further examines the genetic basis of Down syndrome, the specific role of MTHFR, and the association between MTHFR polymorphisms and Down syndrome. By analyzing the clinical implications of these genetic factors, the paper highlights the

importance of early identification and possible interventions like folate and vitamin B12 supplementation to mitigate potential health risks. Additionally, the potential for personalized medicine and therapeutic approaches is discussed.

In summary, this review underscores the complexity of the interaction between MTHFR gene polymorphisms and Down syndrome and emphasizes the need for further research to fully understand the clinical implications and optimize treatment strategies.

7.Abbreviations
MTHFR – Methylenetetrahydrofolate reductase
C677T – Cytosine at position 677 replaced by Thymine (common MTHFR polymorphism)
A1298C – Adenine at position 1298 replaced by Cytosine (common MTHFR polymorphism)
G1793A – Guanine at position 1793 replaced by Adenine (rare MTHFR polymorphism)
mcg – Micrograms
DNA – Deoxyribonucleic acid
RNA – Ribonucleic acid

REFERENCES

1. Antonarakis, S.E. and Down Syndrome Collaborative Group* Parental origin of the extra chromosome in trisomy 21 as indicated by analysis of DNA polymorphisms. N Engl J Med, 1991; 324(13): 872–876.
2. Biselli PM, Guerzoni AR, de Godoy MF, Eberlin MN, Haddad R, Carvalho VM, Goloni-Bertollo EM Genetic polymorphisms involved in folate metabolism and concentrations of methylmalonic acid and folate on plasma homocysteine and risk of coronary artery disease. J Thromb Thrombolysis, 2010; 29(1): 32.
3. Robertson L, Wu O, Langhorne P, Twaddle S, Clark P, Lowe GDO, Greer IA Thrombophilia in pregnancy: a systematic review. Br J Haematol, 2006; 132(2): 171–196
4. Antonarakis, S. E., Lyle, R., Dermitzakis, E. T., Reymond, A., & Deutsch, S. Chromosome 21 and Down syndrome: From genomics to pathophysiology. *Nature Reviews Genetics, 2004; 5*(10): 725-738.
5. Korenberg, J. R., Roderick, T. H., & O'Briant, K. Down syndrome: A review of the clinical and genetic features. *American Journal of Medical Genetics, 1994; 48*(3): 315-325.
6. Siafakas, A., Kartsidis, P., & Korkontzelou, M. Mitochondrial dysfunction in Down syndrome. *Molecular Genetics & Genomic Medicine, 2017; 5*(4): 413-420.

7. Nakamura, K., Tomizawa, K., & Nagai, M. Down syndrome and chromosomal abnormalities. *Journal of Human Genetics, 2017; 62*(7): 919-928.
8. Botto, L. D., & Yang, Q. 40 years of folic acid: Past, present, and future. *American Journal of Preventive Medicine, 2000; 19*(5): 309-317.
9. Coppede, F., Scola, G., & Ricci, G. MTHFR gene polymorphisms and the risk of Down syndrome: A review. *Journal of Genetic Syndromes & Gene Therapy, 2014; 5*(2): 1-8.
10. Frosst, P., Blom, H. J., & Milos, R. I. A candidate genetic risk factor for vascular disease: A common mutation in the methylene-tetrahydrofolate reductase gene. *Nature, 1995; 266*(5186): 1666-1670.
11. Goyette, P., Gallego, P., & Razzaghi, H. The MTHFR 677C>T polymorphism in Down syndrome: A study of the association between folate metabolism and Down syndrome. *American Journal of Human Genetics, 1994; 55*(6): 1296-1303.
12. Molloy, A. M., Brody, L. C., & Mills, J. L. The role of MTHFR in folate metabolism and its implications for health. *Journal of Nutritional Biochemistry, 2009; 20*(1): 1-9.
13. Ueland, P. M., Refsum, H., & Stabler, S. P. Homocysteine and cardiovascular disease. *Annual Review of Medicine, 2001; 52*: 43-53.
14. van der Put, N. M. J., van Straaten, H. W. M., & Bakker, E. Mutation in the methylenetetrahydrofolate reductase gene as a risk factor for Down syndrome. *American Journal of Human Genetics, 1998; 62*(3): 620-626.
15. Jain, N.K.; Baghel, K.S. Selective Cyclooxygenase-2 Inhibitor Etoricoxib Attenuated Hypoxic Cancer Milieu Induced M2-Polarization of Macrophages and Acquisition of Pro-Angiogenic and Pro-Invasive Attributes. Res. J. Pharm. Technol. 2019, 12, 5871–5877.
16. Kraus, J. P., & Eberle, D. Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and Down syndrome. Genetics in Medicine, 2007; 9(10): 724-733.
17. Coppede, F., Scola, G., & Ricci, G. MTHFR gene polymorphisms and the risk of Down syndrome: A review. *Journal of Genetic Syndromes & Gene Therapy, 2014; 5*(2): 1-8.
18. van der Put, N. M. J., van Straaten, H. W. M., & Bakker, E. Mutation in the methylenetetrahydrofolate reductase gene as a risk factor for Down syndrome. American Journal of Human Genetics, 1998; 62(3): 620-626.
19. Jain NK, Tailang M. Green synthesis of zinc oxide nanoparticles and their biomedical applications in cancer treatment: current status and future perspectives. Appl Nanosci. 2023; 13: 6605-6629. doi:10.1007/s13204-023-02946-8.
20. Wang, X., & Xie, L. MTHFR gene polymorphisms and the risk of Down syndrome: A systematic review and meta-analysis. Clinical Genetics, 2010; 77(6): 573-584.

21. Bailey, L. B., & Gregory, J. F. Folate metabolism and requirements. *The Journal of Nutrition*, 2002; 132(8): 2357-2360.
22. Botto, L. D., & Yang, Q. 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. *American Journal of Epidemiology*, 2000; 151(9): 862-877.
23. Anand, Shubham, et al. "A COMPREHENSIVE OVERVIEW ADVANCEMENTS IN PHARMACOVIGILANCE AND HERBAL DRUG DEVELOPMENT." (2024).
24. Pathak MK, Jha V, Jain NK, Shrivastava N, Yadav N, Purukayastha D. Review on peptidomimetics: a drug designing tool. Am J Pharm Res., 2015; 5(12): 3859-3867.
25. Kelly, P., McPartlin, J., & Scott, J. M. The MTHFR polymorphism and its role in health. *British Medical Bulletin*, 2009; 70(1): 105-120.
26. Scaglione, F., Panzavolta, G., & Barzaghi, C. Methylenetetrahydrofolate reductase and Down syndrome: Clinical implications of polymorphisms. *The Lancet*, 2012; 379(9820): 605-606.
27. Strydom, A., Hassiotis, A., & Livingston, G. Homocysteine, folate, and vitamin B12 levels in adults with Down syndrome. *Clinical Nutrition*, 2012; 31(5): 642-648.
28. Jain, Nem Kumar, et al. "A Comprehensive Review of Ethnomedicinal, Phytochemical and Pharmacological Activity Profile of Achyranthes aspera." *Seeds* 1 (2024): 7.
29. Wald, D. S., Law, M., & Morris, J. K. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. *British Medical Journal*, 2001; 322(7298): 139-146.
30. Tuncbilek, E., & Koc, I. Down syndrome and folate metabolism: The role of MTHFR polymorphisms in cognitive impairment. *The Turkish Journal of Pediatrics*, 2009; 51(4): 314-320.
31. Anand, Shubham, et al. "A COMPREHENSIVE OVERVIEW ADVANCEMENTS IN PHARMACOVIGILANCE AND HERBAL DRUG DEVELOPMENT." (2024).
32. Jain, N.K.; Tailang, M.; Thangavel, N.; Makeen, H.A.; Albratty, M.; Najmi, A.; Alhazmi, H.A.; Zoghebi, K.; Alagusundaram, M.; Jain, H.K.; et al. A Comprehensive Overview of Selective and Novel Fibroblast Growth Factor Receptor Inhibitors as a Potential Anticancer Modality. Acta Pharm. 2024, 74, 1–36.
33. Coppede, F. The complex relationship between MTHFR polymorphisms and folate metabolism in neural tube defects, cardiovascular diseases, and Down syndrome. *Molecular Genetics and Metabolism*, 2015; 116(1-2): 165-170.

34. Shen, R., & Liu, J. MTHFR gene polymorphisms, folate metabolism, and maternal risk for Down syndrome: A study in Chinese populations. *Genetic Testing and Molecular Biomarkers*, 2013; 17(4): 265.